These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 16981075)

  • 1. [Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors].
    Bläker M; de Weerth A
    Z Gastroenterol; 2006 Sep; 44(9):1003-4. PubMed ID: 16981075
    [No Abstract]   [Full Text] [Related]  

  • 2. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial.
    Arnold R; Rinke A; Klose KJ; Müller HH; Wied M; Zamzow K; Schmidt C; Schade-Brittinger C; Barth P; Moll R; Koller M; Unterhalt M; Hiddemann W; Schmidt-Lauber M; Pavel M; Arnold CN
    Clin Gastroenterol Hepatol; 2005 Aug; 3(8):761-71. PubMed ID: 16234004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The treatment of carcinoid of the small intestine with octreotide and alpha-interferon. A call for participation in a randomized study].
    Ahrén B
    Dtsch Med Wochenschr; 1996 May; 121(22):744-5. PubMed ID: 8646989
    [No Abstract]   [Full Text] [Related]  

  • 4. [New medical therapy of neuroendocrine gastrointestinal tumors].
    Eriksson B; Janson ET; Skogseid B; Oberg K
    Lakartidningen; 1990 Aug; 87(35):2668-72. PubMed ID: 2214974
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficient symptomatic control of carcinoid tumors with somatostatin in patients with disease progression under alpha-interferon therapy.
    Boehme MW; Schmidt-Gayk H; Bihl H; Eisenhut M; Herfarth CH; Kommere B; Raeth U
    Hepatogastroenterology; 1995; 42(6):1053-61. PubMed ID: 8847018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours.
    Kölby L; Persson G; Franzén S; Ahrén B
    Br J Surg; 2003 Jun; 90(6):687-93. PubMed ID: 12808615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hereditary neuroendocrine gastroenteropancreatic tumors and multiple endocrine neoplasia type 1].
    Scherübl H; Schaaf L; Raue F; Faiss S; Zeitz M
    Dtsch Med Wochenschr; 2004 Mar; 129(13):689-92. PubMed ID: 15026965
    [No Abstract]   [Full Text] [Related]  

  • 8. Is it time to widen the use of somatostatin analogs in neuroendocrine tumors?
    Oberg KE
    J Clin Oncol; 2009 Oct; 27(28):4635-6. PubMed ID: 19704053
    [No Abstract]   [Full Text] [Related]  

  • 9. Tumor Growth Rate (TGR) as an Indicator of Antitumor Activity With Lanreotide Autogel/Depot (LAN) Versus Placebo (Pbo) in Intestinal/Pancreatic NET: Post Hoc Analysis of CLARINET Data.
    Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):6-7. PubMed ID: 27168103
    [No Abstract]   [Full Text] [Related]  

  • 10. Medical treatment of endocrine gastroenteropancreatic tumors.
    Tomassetti P; Campana D; Nori F; Piscitelli L; Salomone L; Pezzilli R; Corinaldesi R
    JOP; 2006 Jan; 7(1):145-9. PubMed ID: 16407637
    [No Abstract]   [Full Text] [Related]  

  • 11. Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency.
    Woltering EA; Hilton RS; Zolfoghary CM; Thomson J; Zietz S; Go VL; Vinik AI; Vinik E; O'Dorisio TM; Mamikunian G
    Pancreas; 2006 Oct; 33(3):250-4. PubMed ID: 17003646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
    Oberg K
    Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosing, treating and managing carcinoid tumours.
    Burgess A
    Nurs Times; 2005 Jul 19-25; 101(29):32-4. PubMed ID: 16052941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of sandostatin on plasma chromogranin-A levels in neuroendocrine tumors.
    Moattari AR; Deftos LJ; Vinik AI
    J Clin Endocrinol Metab; 1989 Oct; 69(4):902-5. PubMed ID: 2778040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors.
    Berković MC; Altabas V; Herman D; Hrabar D; Goldoni V; Vizner B; Zjacić-Rotkvić V
    Coll Antropol; 2007 Jun; 31(2):531-4. PubMed ID: 17847934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of pancreatic apudomas with a somatostatin analog SMS 201-995].
    Varas Lorenzo MJ
    Med Clin (Barc); 1988 Dec; 91(20):796. PubMed ID: 3236932
    [No Abstract]   [Full Text] [Related]  

  • 17. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.
    Butturini G; Bettini R; Missiaglia E; Mantovani W; Dalai I; Capelli P; Ferdeghini M; Pederzoli P; Scarpa A; Falconi M
    Endocr Relat Cancer; 2006 Dec; 13(4):1213-21. PubMed ID: 17158766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
    Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG
    Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced endocrine gastroenteropancreatic tumours using radiolabelled somatostatin analogues.
    Van Eijck CH
    Br J Surg; 2005 Nov; 92(11):1333-4. PubMed ID: 16237740
    [No Abstract]   [Full Text] [Related]  

  • 20. Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide.
    Joensuu H; Kätkä K; Kujari H
    Acta Endocrinol (Copenh); 1992 Feb; 126(2):184-5. PubMed ID: 1371898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.